Stay updated on Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial

Sign up to get notified when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    6 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:48:47.000Z thumbnail image
  6. Check
    13 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dose of GSK1265744 in a study focused on inducing and maintaining virologic suppression in HIV-1 infected, antiretroviral therapy naive subjects.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:42.000Z thumbnail image
  7. Check
    28 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants in the study, specifying requirements such as age, HIV-1 RNA levels, and CD4+ cell count. Previously, the page only listed dates related to study record updates and quality control criteria.
    Difference
    18%
    Check dated 2024-05-22T21:28:42.000Z thumbnail image
  8. Check
    50 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:29:30.000Z thumbnail image

Stay in the know with updates to Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.